Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jennifer A. Wambach is active.

Publication


Featured researches published by Jennifer A. Wambach.


Pediatric Research | 2008

Population and Disease-Based Prevalence of the Common Mutations Associated With Surfactant Deficiency

Tami H. Garmany; Jennifer A. Wambach; Hillary B. Heins; Julie Watkins-Torry; Daniel J. Wegner; Kate W. Bennet; Ping An; Garland Land; Ola Didrik Saugstad; Howard E. Henderson; Lawrence M. Nogee; F. Sessions Cole; Aaron Hamvas

The prevalence of the common mutations in the surfactant protein-B (121ins2), surfactant protein-C (I73T), and ATP-binding cassette member A3 (E292V) genes in population-based or case-control cohorts of newborn respiratory distress syndrome (RDS) is unknown. We determined the frequencies of these mutations in ethnically diverse population and disease-based cohorts using restriction enzyme analysis (121ins2 and E292V) and a 5′ nuclease assay (I73T) in DNA samples from population-based cohorts in Missouri, Norway, South Korea, and South Africa, and from a case–control cohort of newborns with and without RDS (n = 420). We resequenced the ATP-binding cassette member A3 gene (ABCA3) in E292V carriers and computationally inferred ABCA3 haplotypes. The population-based frequencies of 121ins2, E292V, and I73T were rare (<0.4%). E292V was present in 3.8% of newborns with RDS, a 10-fold greater prevalence than in the Missouri cohort (p < 0.001). We did not identify other loss of function mutations in ABCA3 among patients with E292V that would account for their RDS. E292V occurred on a unique haplotype that was derived from a recombination of two common ABCA3 haplotypes. E292V was over-represented in newborns with RDS suggesting that E292V or its unique haplotype impart increased genetic risk for RDS.


Human Mutation | 2013

Novel FOXF1 Mutations in Sporadic and Familial Cases of Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins Imply a Role for its DNA Binding Domain

Partha Sen; Yaping Yang; Colby Navarro; Iris Silva; Przemyslaw Szafranski; Katarzyna E. Kolodziejska; Avinash V. Dharmadhikari; Hasnaa Mostafa; Harry P. Kozakewich; Debra L. Kearney; John Cahill; Merrissa Whitt; Masha Bilic; Linda R. Margraf; Adrian Charles; Jack Goldblatt; Kathleen Gibson; Patrick E. Lantz; A. Julian Garvin; John K. Petty; Zeina N. Kiblawi; Craig W. Zuppan; Allyn McConkie-Rosell; Marie McDonald; Stacey L. Peterson-Carmichael; Jane T. Gaede; Binoy Shivanna; Deborah Schady; Philippe Friedlich; Stephen R. Hays

Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) is a rare and lethal developmental disorder of the lung defined by a constellation of characteristic histopathological features. Nonpulmonary anomalies involving organs of gastrointestinal, cardiovascular, and genitourinary systems have been identified in approximately 80% of patients with ACD/MPV. We have collected DNA and pathological samples from more than 90 infants with ACD/MPV and their family members. Since the publication of our initial report of four point mutations and 10 deletions, we have identified an additional 38 novel nonsynonymous mutations of FOXF1 (nine nonsense, seven frameshift, one inframe deletion, 20 missense, and one no stop). This report represents an up to date list of all known FOXF1 mutations to the best of our knowledge. Majority of the cases are sporadic. We report four familial cases of which three show maternal inheritance, consistent with paternal imprinting of the gene. Twenty five mutations (60%) are located within the putative DNA‐binding domain, indicating its plausible role in FOXF1 function. Five mutations map to the second exon. We identified two additional genic and eight genomic deletions upstream to FOXF1. These results corroborate and extend our previous observations and further establish involvement of FOXF1 in ACD/MPV and lung organogenesis.


Pediatrics | 2012

Single ABCA3 Mutations Increase Risk for Neonatal Respiratory Distress Syndrome

Jennifer A. Wambach; Daniel J. Wegner; Kelcey DePass; Hillary B. Heins; Todd E. Druley; Robi D. Mitra; Ping An; Qunyuan Zhang; Lawrence M. Nogee; F. Sessions Cole; Aaron Hamvas

BACKGROUND AND OBJECTIVE: Neonatal respiratory distress syndrome (RDS) due to pulmonary surfactant deficiency is heritable, but common variants do not fully explain disease heritability. METHODS: Using next-generation, pooled sequencing of race-stratified DNA samples from infants ≥34 weeks’ gestation with and without RDS (n = 513) and from a Missouri population-based cohort (n = 1066), we scanned all exons of 5 surfactant-associated genes and used in silico algorithms to identify functional mutations. We validated each mutation with an independent genotyping platform and compared race-stratified, collapsed frequencies of rare mutations by gene to investigate disease associations and estimate attributable risk. RESULTS: Single ABCA3 mutations were overrepresented among European-descent RDS infants (14.3% of RDS vs 3.7% of non-RDS; P = .002) but were not statistically overrepresented among African-descent RDS infants (4.5% of RDS vs 1.5% of non-RDS; P = .23). In the Missouri population-based cohort, 3.6% of European-descent and 1.5% of African-descent infants carried a single ABCA3 mutation. We found no mutations among the RDS infants and no evidence of contribution to population-based disease burden for SFTPC, CHPT1, LPCAT1, or PCYT1B. CONCLUSIONS: In contrast to lethal neonatal RDS resulting from homozygous or compound heterozygous ABCA3 mutations, single ABCA3 mutations are overrepresented among European-descent infants ≥34 weeks’ gestation with RDS and account for ∼10.9% of the attributable risk among term and late preterm infants. Although ABCA3 mutations are individually rare, they are collectively common among European- and African-descent individuals in the general population.


Pediatric Diabetes | 2009

Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.

Jennifer A. Wambach; Bess A. Marshall; Joseph C. Koster; Neil H. White; Colin G. Nichols

Wambach JA, Marshall BA, Koster JC, White NH, Nichols CG. Successful sulfonylurea treatment of an insulin‐naïve neonate with diabetes mellitus due to a KCNJ11 mutation.


Pediatric Research | 2012

An intronic ABCA3 mutation that is responsible for respiratory disease

Amit Agrawal; Aaron Hamvas; F. Sessions Cole; Jennifer A. Wambach; Daniel J. Wegner; Carl Coghill; Keith Harrison; Lawrence M. Nogee

Introduction:Member A3 of the ATP-binding cassette family of transporters (ABCA3) is essential for surfactant metabolism. Nonsense, missense, frameshift, and splice-site mutations in the ABCA3 gene (ABCA3) have been reported as causes of neonatal respiratory failure (NRF) and interstitial lung disease. We tested the hypothesis that mutations in noncoding regions of ABCA3 may cause lung disease.Methods:ABCA3-specific cDNA was generated and sequenced from frozen lung tissue from a child with fatal lung disease with only one identified ABCA3 mutation. ABCA3 was sequenced from genomic DNA prepared from blood samples obtained from the proband, parents, and other children with NRF.Results:ABCA3 cDNA from the proband contained sequences derived from intron 25 that would be predicted to alter the structure and function of the ABCA3 protein. Genomic DNA sequencing revealed a heterozygous C>T transition in intron 25 trans to the known mutation, creating a new donor splice site. Seven additional infants with an ABCA3-deficient phenotype and inconclusive genetic findings had this same variant, which was not found in 2,132 control chromosomes.Discussion:These findings support that this variant is a disease-causing mutation that may account for additional cases of ABCA3 deficiency with negative genetic studies.


Pediatric Research | 2010

Surfactant Protein-C Promoter Variants Associated With Neonatal Respiratory Distress Syndrome Reduce Transcription

Jennifer A. Wambach; Ping Yang; Daniel J. Wegner; Ping An; Brian P. Hackett; F. S. Cole; Aaron Hamvas

Dominant mutations in coding regions of the surfactant protein-C gene, SFTPC, cause respiratory distress syndrome (RDS) in infants. However, the contribution of variants in noncoding regions of SFTPC to pulmonary phenotypes is unknown. By using a case-control group of infants ≥34 weeks gestation (n = 538), we used complete resequencing of SFTPC and its promoter, genotyping, and logistic regression to identify 80 single nucleotide polymorphisms (SNPs). Three promoter SNPs were statistically associated with neonatal RDS among European descent infants. To assess the transcriptional effects of these three promoter SNPs, we selectively mutated the SFTPC promoter and performed transient transfection using MLE-15 cells and a firefly luciferase reporter vector. Each promoter SNP decreased SFTPC transcription. The combination of two variants in high linkage dysequilibrium also decreased SFTPC transcription. In silico evaluation of transcription factor binding demonstrated that the rare allele at g.−1167 disrupts a SOX (SRY-related high mobility group box) consensus motif and introduces a GATA-1 site, at g.−2385 removes a MZF-1 (myeloid zinc finger) binding site, and at g.−1647 removes a potential methylation site. This combined statistical, in vitro, and in silico approach suggests that reduced SFTPC transcription contributes to the genetic risk for neonatal RDS in developmentally susceptible infants.


American Journal of Medical Genetics Part A | 2014

Two deletions overlapping a distant FOXF1 enhancer unravel the role of lncRNA LINC01081 in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins.

Przemyslaw Szafranski; Avinash V. Dharmadhikari; Jennifer A. Wambach; Chris T. Towe; Frances V. White; R. Mark Grady; Pirooz Eghtesady; F. Sessions Cole; Gail H. Deutsch; Partha Sen; Pawel Stankiewicz

Position effects due to disruption of distant cis‐regulatory regions have been reported for over 40 human gene loci; however, the underlying mechanisms of long‐range gene regulation remain largely unknown. We report on two patients with alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) caused by overlapping genomic deletions that included a distant FOXF1 transcriptional enhancer mapping 0.3 Mb upstream to FOXF1 on 16q24.1. In one patient with atypical late‐onset ACDMPV, a ∼1.5 Mb deletion removed the proximal 43% of this enhancer, leaving the lung‐specific long non‐coding RNA (lncRNA) gene LINC01081 intact. In the second patient with severe neonatal‐onset ACDMPV, an overlapping ∼194 kb deletion disrupted LINC01081. Both deletions arose de novo on maternal copy of the chromosome 16, supporting the notion that FOXF1 is paternally imprinted in the human lungs. RNAi‐mediated knock‐down of LINC01081 in normal fetal lung fibroblasts showed that this lncRNA positively regulates FOXF1 transcript level, further indicating that decrease in LINC01081 expression can contribute to development of ACDMPV.


Pediatric Pulmonology | 2008

Recombination as a mechanism for sporadic mutation in the surfactant protein-C gene

Amy D. McBee; Daniel J. Wegner; Christopher S. Carlson; Jennifer A. Wambach; Ping Yang; Hillary B. Heins; Ola Didrik Saugstad; Michelle Trusgnich; Julie Watkins-Torry; Lawrence M. Nogee; Howard E. Henderson; F. Sessions Cole; Aaron Hamvas

To determine haplotype background of common mutations in the genes encoding surfactant proteins B and C (SFTPB and SFTPC) and to assess recombination in SFTPC.


Diabetes Care | 2015

Remission of Severe Neonatal Diabetes With Very Early Sulfonylurea Treatment

Bess A. Marshall; Rebecca P. Green; Jennifer A. Wambach; Neil H. White; Maria S. Remedi; Colin G. Nichols

Mutations in KCNJ11 and ABCC8 can cause neonatal diabetes mellitus (NDM) (1) that may respond to sulfonylureas (2). We report three NDM infants treated with glyburide very early in life who were able to maintain good glycemic control with minimal dosing. This 6-year-old male (Case-1-male) was previously reported at birth (3). Mother and sister (Case-1-female) both had NDM and were given insulin for 24 and 6 years, respectively, then treated with high-dose glyburide; mother still requires some insulin. Case-1-male had NDM at 3 days and was given glyburide 0.2 mg/kg/day, weaned to 0.05 mg/kg/day, and maintained normal hemoglobin A1c for 5 years (Fig. 1 A ) continuing glyburide 0.075 mg thrice daily (mixing a crushed 5 mg tablet with 10 cc water, giving 0.15 cc for each dose, 0.012 mg/kg/day). All had a heterozygous mutation in KCNJ11 (R201H). Figure 1 A : Hemoglobin A …


American Journal of Medical Genetics Part A | 2015

De novo 9q gain in an infant with tetralogy of Fallot with absent pulmonary valve: Patient report and review of congenital heart disease in 9q duplication syndrome.

Ina E. Amarillo; Shawn O'Connor; Caroline K. Lee; Marcia C. Willing; Jennifer A. Wambach

Genomic disruptions, altered epigenetic mechanisms, and environmental factors contribute to the heterogeneity of congenital heart defects (CHD). In recent years, chromosomal microarray analysis (CMA) has led to the identification of numerous copy number variations (CNV) in patients with CHD. Genes disrupted by and within these CNVs thus represent excellent candidate genes for CHD. Microduplications of 9q (9q+) have been described in patients with CHD, however, the critical gene locus remains undetermined. Here we discuss an infant with tetralogy of Fallot with absent pulmonary valve, fetal hydrops, and a 3.76 Mb de novo contiguous gain of 9q34.2‐q34.3 detected by CMA, and confirmed by karyotype and FISH studies. This duplicated interval disrupted RXRA (retinoid X receptor alpha; OMIM #180245) at intron 1. We also review CHD findings among previously reported patients with 9q (9q+) duplication syndrome. This is the first report implicating RXRA in CHD with 9q duplication, providing additional data in understanding the genetic etiology of tetralogy of Fallot, CHD, and disorders linked to 9q microduplication syndrome. This report also highlights the significance of CMA in the clinical diagnosis and genetic counseling of patients and families with complex CHD.

Collaboration


Dive into the Jennifer A. Wambach's collaboration.

Top Co-Authors

Avatar

Aaron Hamvas

Northwestern University

View shared research outputs
Top Co-Authors

Avatar

Daniel J. Wegner

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

F. Sessions Cole

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Hillary B. Heins

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Frances V. White

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Lawrence M. Nogee

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

F. S. Cole

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Ping Yang

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Todd E. Druley

Washington University in St. Louis

View shared research outputs
Researchain Logo
Decentralizing Knowledge